Europe
All three companies have invested millions in the facilities to expand their global footprint.
PharmaMar and Bionical Emas, a global specialist Clinical Research Organization have announced the launch of an Expanded Access Program for lurbinectedin to treat patients in the United States with relapsed Small Cell Lung Cancer, who are unable to enter clinical trials and there are no appropriate alternative treatments.
Researchers at Technical University of Munich recently developed a gene therapy that might cure DMD.
The approval was based on two randomized open-label clinical trials that evaluated the combination of empagliflozin, linagliptin and metformin and their individual components in healthy adults.
Bionetix, ProQinase and MercachemSyncom announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia.
Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® (ALOXI®) in Russia and CIS region from January 2020
Partnership plans molecular biological characterisation of up to 8000 clinically relevant isolates of pathogens resistant to multiple antibiotics using the latest sequencing technology.
QuantuMDx Group Limited announces a business update and the appointments of Jonathan O’Halloran as Chief Executive Officer and Neil Butler as Chairman of the Board, as the company begins its transition to commercialisation..
A new study published in Seizure gives insight into the short-term outcome of patients treated for status epilepticus in Kuopio University Hospital in Finland.
Evotec SE and Indivumed GmbH announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics for the treatment of non-small cell lung cancer.
PRESS RELEASES